+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Immunotoxicology Strategies for Pharmaceutical Safety Assessment

  • ID: 664404
  • Book
  • September 2008
  • Region: Global
  • 432 Pages
  • John Wiley and Sons Ltd
1 of 3
A hands–on reference on current immunotoxicology approaches for testing pharmaceuticals

An important resource for toxicologists in pharmaceutical and biotechnology areas, this book discusses recently introduced systems for immunotoxicology testing and their applications. Immunotoxicology pharmaceutical safety assessments are important for streamlining the development process and reducing drug candidate attrition. After an introduction to immunotoxicology, Immunotoxicology Strategies for Pharmaceutical Safety Assessment:

  • Provides an overview of current regulatory expectations for immunotoxicity evaluation of pharmaceuticals
  • Relates the preclinical immunotoxicity safety assessments to clinical development
  • Offers examples of nonclinical models to study the toxic impacts that pharmaceuticals can have on the immune system

  • Includes chapters on safety of vaccines, testing for drug hypersensitivity, and testing for developmental immunotoxicity

  • Covers diverse methodologies applied in immunotoxicology studies: flow cytometry to characterize responses of immune cells to drug treatment; immunoassays to address immunogenicity of biopharmaceuticals; molecular immunology to evaluate immune dysregulation at the subcellular level; and in vivo models of immune disorders to characterize potential impairment of host defense to infections, tumors, and autoimmune diseases

With chapters contributed by experts from across the pharmaceutical industry, this resource presents immunotoxicity testing from a practical, real–world perspective. This is the current reference for practicing toxicologists in the pharmaceutical industry, industrial and regulatory scientists in drug development, professionals in contract research organizations (CROs) in the pharmaceutical and biotechnology fields, and investigative and regulatory toxicologists.

Note: Product cover images may vary from those shown
2 of 3


Introduction to Immunotoxicology (Jack H. Dean).

Part I: Current regulatory Expectations for Immunotoxicity Evaluation of Pharmaceuticals.

1. Current Regulatory Expectations for Immunotoxicology Evaluation of Pharmaceuticals (Kenneth L. Hastings).

Part II: Weight of Evidence Review: A New Strategy In Immunotoxicology.

2.1. Clinical Pathology as Crucial Insight into Immunotoxicity Testing ( Ellen Evans).

2.2. Histomorphology of the Immune System: A Basic Step in Assessing Immunotoxicity (Patrick Haley).

2.3. Need for Spectacled Immunotoxicity tests (Kazuichi Nakamura).

2.4. Specific Drug–Induced Immunotoxicity: Immune–Mediated Hemolytic Anemia (Raj Krishnaraj).

Part III: Nonclinical Core Immunotoxicity Testing in Drug Development.

3.1.1. T Cell–Dependent Antibody Response tests (Joseph R. Piccotti).

3.1.2. Natural Killer Cell Assay and Other Innate Immunity Tests (Lisa Plitnick).

3.1.3. Cellular Immune Response In Delayed–Type Hypersensitivity Test (Karen Price).

3.2. Evaluation of Drug Effects on Immune Cell Phenotypes (Laurie Iciek).

Part IV: Extended Immunotoxicology Assessment: EX VIVO Models.

4.1. Functional Cellular Responses and Cytokine Profiles (Elizabeth R. Gore).

4.2. Application of Flow Cytometry in Drug Development (Padma Narayanan, Renold J. Capocasale, Nianyu Li, and Peter J. Bugelski).

Part V: Extended Immunotoxicology Assessment: IN VIVO Models.

5.1. Animal Models of Host Resistance (Gary R. Burleson and Florence G. Burleson).

5.2. Approaches to Evaluation of Autoimmunity (Danuta J. Herzyk).

Part VI: Immunotoxicity Testing in Biopharmaceutical Development.

6.1. Differentiating between Desired Immunomodulation and Potential Immunotoxicity (Jeanine L. Bussiere and Barbara Mounho).

6.2. Relevant Immune tests across Different Species ad Surrogate Models (Jeanine L. Bussiere).

6.3. Antidrug Antibody Responses in Nonclinical Studies and Their Implications (Barvara Mounho).

Part VII: Development of  Vaccines.

7.1. Pharmacological Immunogenicity and Adverse Responses to Vaccines (Mary Kate Hart, Mark Bolanowski, and Robert V. House).

7.2. Immunotoxicological Concerns for Vaccines and Adjuvants (Catherine Kaplanski, Jose Lebron, Jayanthi Wolf, an Brian Ledwith).

Part VIII: Testing For Drug Hypersensitivity.

8.1. Systemic Hypersensitivity (Raymond Pieters).

8.2. Nonclinical Models to Assess Respiratory Hypersensitivity Potential (Curtis C. Maier).

Part IX: Testing for developmental Immunotoxicity.

9.1. Developmental Immunotoxicity in Rodents (Rodney R. Dietert and Leigh Ann Burns–Naas).

9.2. Developmental Immunotoxicity in Nonhuman Primates (Pauline L. Martin and Eberhard Buse).

Part X: New Methods in Assessing Immunomodulation, Immunotoxicity, and Immunogenicity.

10.1. Alternative Animal Models for Immunomodulation and Immunotoxicity (Peter J. Bugelski).

10.2. Animal Models for Preclinical Comparative Immunogenicity testing (Daniel Wierda).

10.3. T Cell Epitopes and Minimization of Immunogenicity (Harald Kropshoffer and Thomas Singer).

Part XI: Bridging Immunotoxicology to Clinical Drug Development.

11. Bridging Immunotoxicology to Clinical Drug Development (Ian Gourley and Jacques Descotes).


Note: Product cover images may vary from those shown
3 of 3


4 of 3
Danuta J. Herzyk
Jeanine L. Bussiere
Note: Product cover images may vary from those shown